Growing Revenue & Business Development with Drug Profiling
Patient panels and prescription profiles identifying growing demand, leads to better business development. Hospitals see patients across episodes, yet early treatment of chronic conditions are handled by Physicians and Group Practices. Alignment of care with ambulatory expansion and growth leads to better hospital development.
As health systems acquire provider groups, knowing the leading clinical indicators for growth sheds light on local markets.
The Florida Top 5 Drugs and their clinical function:
Apixaban – is an anticoagulant (blood thinner) that reduces blood clotting and reduces the risk of stroke and systemic embolism
Lenalidomide – a cancer drug and is also known by its brand name, Revlimid. It is a treatment for myeloma and blood disorders called myelodysplastic syndromes.
Insulin Glargine – is a long-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes.
Rivaroxaban – A blood thinner used to treat and prevent blood clots. This may lower the risk of stroke, deep vein thrombosis (DVT), pulmonary embolism (PE), and similar conditions.
Elviteg/Cob/Emtric/Tonofo – Elvitegravir/cobicistat/emtricitabine/tenofovir, also known as the Quad pill, is a fixed dose combination drug for the treatment of HIV/AIDS.
Cleveland Clinic: Florida – Group Practice Profile
- Florida state profile is general and crosses many specialties, yet
- Cleveland Clinic Group: has a high concentration of pulmonary specialists
- Half of prescription costs are drugs that treat pulmonary hypertension
- The drug utilization; brand, volumes, cost, days inform the service line
- A profile of the top prescribers in the group and drug choice is revealing
Cleveland Clinic: Florida Group Practice Part D – Individual Prescriber Profile
Tracking utilization by local providers offers answers to key affiliation and acquisition questions that can grow utilization, and lead to better development and care alignment with practitioners.
Franklin:BI™ aggregates and integrates all the latest metrics of quality, safety, outcomes, and experience collected by CMS in the fastest and best platform.
*Medicare Part D is subscribed to by 70% of the FFS and MA population. There are $155 billion in final-action payments for filled prescriptions from 2017 organized by: NPI provider, group practice, drug, location, volume, frequency/days’ supply and costs. This data represents “pills on the street” or dispensed drugs prescribed by licensed practitioners. Drugs are listed by brand (if applicable) or generic name. Covering 42 million beneficiaries, Part D claims account for approximately 25% of all prescriptions written in the US or about 1.5 billion prescriptions written by 1.1 million doctors, nurses and other health care providers.